FDA Needs More Time to Review Bristol-Myers’s Ipilimumab

Drug maker Bristol-Myers Squibb Co. said the U.S. Food and Drug Administration needs additional time to finish a review of the license application for the company’s melanoma treatment, pushing back its decision date by three months.
ADVFN